Across the trials, primary and secondary efficacy endpoints were analyzed in the modified intention-to-treat population and were tested in a combination of sequential, hierarchical and/or simultaneous approaches across comparisons to control type I error; efficacy endpoints that achieved p < 0.05 but either failed or were excluded from the type I error control strategy were deemed nominally significant [ 17 , 18 ].
1
—
—